News - Avastin

Filter

Current filters:

Avastin

Popular Filters

30 to 54 of 60 results

Chugai pushed into filing for Avastin glioblastoma indication in Japan

21-09-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

Asia-PacificAvastinChugai PharmaceuticalOncologyPharmaceuticalRegulationRoche

Lilly's Alimta combo lung cancer trial fails to meet primary endpoint

07-09-2012

There was disappointing news for US drug major Eli Lilly (NYSE: LLY) yesterday ,as the company announced…

AlimtaAvastinEli LillyOncologyPharmaceuticalResearch

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost

21-08-2012

The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

Pfizer says Torisel combo fails in Ph III for kidney cancer

13-08-2012

In a second research disappointment within a matter of days, US drugs behemoth Pfizer (NYSE: PFE) revealed…

AvastinNephrology and HepatologyOncologyPfizerPharmaceuticalResearchTorisel

Adding Roche's Avastin to radio/chemotherapy extends PFS for brain cancer patients

13-08-2012

Swiss drug major Roche (ROG: SIX) announced on Friday that the Phase III AVAglio study of its blockbuster…

AvastinOncologyPharmaceuticalResearchRoche

Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report

24-07-2012

After six months on the market, 76% of retinal specialists in the USA have prescribed US biotech firm…

AvastinBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

NICE draft guidance continues negative on Roche's Avastin for metastatic breast cancer

06-07-2012

Final draft guidance published today (July 6) by the UK's drugs watchdog the National Institute for Health…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

Global neuroendocrine carcinoma market to reach $475 million by 2019; report

04-07-2012

The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market…

AvastinBioSynthemaIpsenLutatheraMarkets & MarketingOncologyPharmaceuticalRocheSomatuline

New study fuels already heated debate - Avastin vs Lucentis

19-06-2012

At the center of the debate of how to potentially save the health care system millions of dollars are…

AvastinLucentisNovartisOphthalmicsPricingResearchRoche

Fake Avastin reignites "Track-and-Trace" debate, but the clock is ticking

14-06-2012

The US Food and Drug Administration announced in February that counterfeit vials of Roche/Genentech's…

AvastinLegalNorth AmericaPharmaceuticalRegulationRoche

Second trial finds Avastin and Lucentis similar for wet-AMD

08-05-2012

One-year results from the UK.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN)…

AvastinLucentisNovartisOphthalmicsPharmaceuticalPricingResearchRoche

US retinal therapeutics market buoyant, says F&S

07-05-2012

Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering…

AvastinGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRoche

Avastin and Lucentis equivalent in treating age-related macular degeneration

02-05-2012

At two years, the cancer drug Avastin (bevacizumab) and the ophthalmic agent Lucentis (ranibizumab injection),…

AvastinLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Novartis posts sharp drop in 1st-qtr profit; challenges UK off-label Avastin use

24-04-2012

Swiss drug major Novartis (NOVN: VX) has reported a sharp fall in first-quarter 2012 profits, due in…

AvastinEuropeFinancialGenericsLegalLucentisNovartisOphthalmicsPharmaceutical

NICE turns down Roche breast cancer drug Avastin, citing too many uncertainties

18-04-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE), said this morning…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

SHA to fund Roche breast cancer drug Avastin in London

12-04-2012

Women with aggressive metastatic breast cancer in the UK capital London now have access to a drug which…

AvastinOncologyPharmaceuticalPricingRegulationRoche

Chinese colorectal cancer drug market forecast to grow to over $400 million in 2016

04-04-2012

The colorectal cancer drug market in China will grow from a value of $261 million in 2011 to $404 million…

Asia-PacificAvastinErbituxMarkets & MarketingMerck KGaAOncologyPharmaceuticalRoche

Reimbursement and/or budget-related factors restrict use of angiogenesis inhibitor in Brazil and Mexico; Study

28-03-2012

Depending on the tumor type, around one-quarter to one-third of surveyed Brazilian and Mexican oncologists'…

AvastinMarkets & MarketingNexavarOncologyPharmaceuticalPricingSouth AmericaSutent

Patient safety group calls for urgent action on unlicensed medicines

22-03-2012

The European Alliance for Access to Safe Medicines (EAASM) is calling for urgent measures to protect…

AvastinEuropeHealthcareOphthalmicsPharmaceuticalRegulation

Counterfeit Avastin found in USA by FDA

16-02-2012

The US Food and Drug Administration said yesterday that it is warning health care professionals and patients…

AvastinGenentechMarkets & MarketingNorth AmericaOncologyPharmaceuticalRegulationRoche

US FDA revokes Roche/Genentech Avastin license for metastatic breast cancer

21-11-2011

After months of deliberations, the US Food and Drug Administration (FDA Commissioner is revoking the…

AvastinBiotechnologyGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

30 to 54 of 60 results

Back to top